|

Interview With Payton Nyquvest

ByPsychedelic Spotlight

Similar Posts

  • Kevin O’Leary Thinks MindMed, Compass Pathways & atai Will Merge | Is this a Good Idea?

    Listen, Videos

    Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
    www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

    Join our Newsletter (scroll to the bottom of the page and sign up):
    https://psychedelicspotlight.com/

    Follow us on Twitter:
    James: @Psy_Invest
    Maria: @psy_holy
    The Psychedelic Investor: @PsycInvestor
    Psychedelic Spotlight: @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    Back to the potential MindMed, Compass Pathways & atai merger that Kevin O
    Leary speculates on…

    Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?

    The “Shark Tank” star predicts three of the biggest psychedelic companies will merge into a mega-corporation, but our resident Psychedelic Investor wonders: Should they?

    Famed investor Kevin O’Leary made a bold prediction last Tuesday, saying that psychedelic companies MindMed, atai Life Sciences and Compass Pathways will merge. For psychedelic stock investors, this would be a tsunami-sized event that would have ripple effects throughout the industry.

    The Shark Tank star made the comments at the inaugural Benzinga Psychedelics Capital Conference in Miami, arguing that the companies “each need another $200 million by the time they get this to medicine.” In other words, as I have written before, the psychedelic medicines industry is heavily capital intensive, and getting multiple drugs from pre-clinical trials through Phase 3 trials and approved by the FDA can cost hundreds of millions of dollars.

    Even though these companies are three of the best-financed in the industry — atai (Nasdaq: atai) has $362 million, Compass (Nasdaq: CMPS) has $273 million and MindMed (Nasdaq: MNMD, NEO: MMED) has $133 million — the celebrity investor believes that in order to succeed the companies may have to become one.

    Read the entire article here: https://psychedelicspotlight.com/kevin-oleary-predicts-3-biggest-psychedelic-companies-will-merge-atai-mindmed-compass-pathways/

    One man claims magic mushrooms healed his lost sense of smell. Read the full story here.
    https://whyy.org/segments/could-magic-mushrooms-cure-covid-related-smell-loss/

    A new anti-depressant study is out. Read the full study here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265928#sec011

    #Mindmed #kevinoleary #psychedelicstocks

  • The Top 10 Psychedelics Stocks’ Financials COMPARED ( Atai, CMPS, MNMD, NUMI, RVV, DMT, TRIP+)

    Listen, Videos

    What’s up psychedelic investors! In this episode, we’ll be comparing the top 10 psychedelic stocks’ financials.
    Will look at the 4 most important financial stats for each of the top 10 companies in the Psychedelic Medicines field, selected by market cap.

    First, we will look at the market cap, because that tells us how valuable the market judges the company to be, and it tells us how easily a company can raise capital.
    Next, we will look at cash on hand.
    Third, we will look at how much a company is spending.
    Finally, we will look at revenue where applicable
    All figures are in American dollars.

    So which stocks we’ll be comparing, you may ask? We’ll look at:
    – Atai Life Sciences ( NASDAQ: ATAI)
    – Compass Pathways (NASDAQ: CMPS)
    -MindMed (NASDAQ: MNMD), ( NEO: MMED)
    – Cybin Inc (NYSE: CYBN)
    – Numinus Wellneass (TSX: NUMI) (OTC: LKYSF)
    – Revive Therapeutics (CN: RVV) (OTC: RVVTF)
    – Small Pharma ( TSX: DMT)
    -Mydecine (OTC: MYCOF) (NEO: MYCO)
    – Red Light Holland ( CSE: TRIP) (OTC: TRUFF)

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #ATAISTOCK #PsychedelicStocks

  • Interview with Dr. Erica Zelfand

    Listen, Podcasts

    This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.

  • Does Microdosing Mushrooms Work? ( Interview with Sena Maria)

    Listen, Videos

    Hello Psychedelic Investors! The topic of today’s video is “Does microdosing mushrooms work?” We usually talk about investing in psychedelic stocks and companies inspired by microdosing psychedelics with the mission to cure depression, anxiety, adhd, etc. But we never really dove deep into the science of microdosing. Does Microdosing Magic Mushrooms really work? So before investing in companies like MindMed (MMED/MMEDF), Compass Pathways (CMPS), Numi, Field Trip Health (FTRP) or Atai Life Sciences, listening to someone who’s got a personal experience with psychedelics might not be such a bad idea.

    One of the reasons behind the interview with pro in the Microdosing psilocybin realm is that recent studies have shown that the benefits of microdosing can be attributed completely to placebo effects. That’s why I decided to have a talk with Sena Maria. Sena is passionate about working with the fungi realm to support our collective evolution. Coming from Google in Silicon Valley she took a big life pivot and has spent the last 5 years learning from the plants. After supporting hundreds of people in getting started with microdosing, she now shares what she’s learned on her YouTube channel The Medicine of Being Human and her instagram @sena__maria.

    So what do you guys think? Is Microdosing Psychedelics the Future of Medicine? Hopefully some of the new MMED or CMPS or any other psychedelic stocks investors got some value in this! What do you guys think?

    You can learn more about microdosing in her popular webinar Microdosing For Resilience at www.medicineofbeinghuman.com

    Timestamps:

    0:00 – Intro
    1:11 – What is Microdosing & How does it Work?
    2:55 – Microdosing Benefits
    7:28 – Why Microdosing? ( Regimen & Protocols)
    14:12 – Discussing microdosing & placebo effects
    19:21 – Personal Microdosing Experiences & Consistency
    24:09 – Microdosing Advice for Beginners

    #PsychedelicStocks #MindMed #MicrodosingPsilocybin

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

  • BIG UPDATE On The LARGEST Psychedelic Therapy Clinical Trial: CMPS’ Psilocybin-Depression Study

    Listen, Videos

    HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).

    This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.

    In this episode we will discuss:
    – The details of this trial and why it is so important;
    – The big update that we have for you;
    – When we can expect results;
    – Where the field goes from here in the near future.

    Timestamps:

    0:00 – Intro
    1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
    6:57 – The major Update on CMPS’ Clinical Trial
    8:07 – Anticipated results date & what these results will mean for the psychedelic industry

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #CMPS #PsychedelicTherapy